As Hong Kong stocks rally, newly listed stocks see significant gains. Below is their performance since listing.

Laopu Gold (06181.HK)

If anything glitters in China’s otherwise dour retail jewelery landscape, chances are it just might be from Laopu Gold Co.

The Bejing-based jeweler, whose Chinese name translates to “old shop,” is luring shoppers as it outshines market leader Chow Tai Fook Jewellery Group Ltd. and other local brands, from sales growth to stock performance.

Laopu Gold is enchanting both investors and luxury lovers, making it one of the leading lights on Hong Kong's market stage. The spark? An optimistic profit forecast projecting an impressive 236% to 260% jump in net profit for 2024. This substantial revision is catching eyes amid current economic uncertainties. But it's not just about profits. Laopu Gold has won over affluent Chinese consumers, serving as both a status symbol and a financial safe haven. With Nomura's endorsement, Laopu could soon stand as China's premier luxury name.

Since its IPO at HK$40.50, its shares closed at HK$692 on Tuesday, March 11, soaring more than 1611%.

Mao Geping (01318.HK)

Chinese beauty brand Mao Geping went public in December 2024, with its stock surging, once earning the title of 'the best IPO on HKEX in four years.

China's premium beauty market is valued around 195 billion yuan ($26.85 billion), according to Mao Geping's prospectus. The company, which is led by one of the most famous make-up artists in China, is listing at a time when Hong Kong is seeing some improvement in IPO activity this year.

It has 372 points of sale across department stores in China, while around half of its sales come from e-commerce platforms, including Tmall, Douyin, JD.com, and Xiaohongshu.

Since its IPO, Mao Geping's stock has surged 250%.

HealthyWay (02587.HK)

The digital healthcare service platform operator HealthyWay went public in Hong Kong late last year, and its stock has since surged nearly 158%.

HealthyWay became acquainted with Baidu when the latter made a $60 million investment during the company’s A-round funding in 2015. Baidu is now the company’s second-largest shareholder with 12.5% of HealthyWay’s stock, behind only founder Zhang Wanneng with 34.7% of its shares.

HealthyWay’s revenue grew 14.5% year-on-year to 611 million yuan ($86.3 million) in the first half of 2024. Content services is its biggest single source, accounting for about half of the total, followed by information technology services at 21.1%, according to its application document.

Shenzhen Dobot (02432.HK)

On December 23, 2024, Shenzhen Dobot, headquartered in Nanshan District of Shenzhen, was listed on the Main Board of The Stock Exchange of Hong Kong, becoming the "First Collaborative Robot Stock." Since its IPO, Mao Geping's stock has surged nearly 116%.

Dobot Robotics has established branches and R&D centers in 12 countries and regions globally, deeply embedding itself in the international market. As of 2023, the company ranks first among all collaborative robot companies in China and second in the global industry, with a total global shipment of 72,000 units and business spanning over 80 countries and regions.

The company’s shares have been included in the list of eligible securities for Southbound Trading under both the Shanghai Connect and the Shenzhen Connect.

Dobot recently launched the world's first embodied intelligent humanoid robot "Dobot Atom", which features "dexterous manipulation + straight-knee walking". It also unveiled a new generation of embodied intelligent robotic product "RoboPilot".

Mixue Group (02097.HK)

China’s largest bubble tea chain, Mixue, has skyrocketed since its IPO, with its stock now doubling (+107.7%).

Founded in 1997 as a small ice shop in Zhengzhou, Henan province, Mixue has grown into a franchise giant with over 45,000 stores globally by September 2024, surpassing Starbucks' 40,576 stores worldwide. In the first nine months of 2024, Mixue reported a net profit of 3.49 billion yuan, up from 3.19 billion yuan in the same period the previous year, according to its IPO filings.

Shares of Mixue were highly sought after, with the Hong Kong offering over 5,200 times oversubscribed. The international offering was more than 35 times oversubscribed.

XunfeiHealth (02506.HK)

Xunfei Healthcare Technology, spun off from Chinese artificial intelligence firm iFlytek, made its debut on the Hong Kong Stock Exchange on December 30, 2024. The shares has surged nearly 102% since its IPO.

Founded in 2016, Xunfei leverages its parent company’s AI expertise to develop full-cycle healthcare solutions, from disease prevention and diagnosis to post-treatment management. However, while it capitalized on the growing demand for smart healthcare, its financial performance shows slowing revenue growth and persistent losses. Revenues increased to RMB 556 million (USD 77.8 million) in 2023, but growth slowed to 17.7% from 26.8% the previous year. Net losses have also remained significant, totaling RMB 134 million (USD 18.8 million) in the first half of 2024.

Xunfei Healthcare Technology has joined in the Hang Seng Composite Index. This inclusion signifies a strong recognition of Xunfei Healthcare Technology’s business performance and growth prospects, which is expected to increase shareholder base, enhance share liquidity, and boost the company’s reputation and investment value in the capital market.

BrainAurora (06681.HK)

Brainaurora Medical Technology debuted on the Hong Kong stock exchange Jan. 8 with a HK$583.18 million (US$74.93 million) IPO, offering about 181.11 million shares at HK$3.22 per share. The shares has surged more than 95% since its IPO.

The prospectus describes BrainAurora, founded in 2012, as a pioneer in the field of medically applied brain science in China, using artificial intelligence to detect and address a wide range of cognitive issues caused by neurodegenerative diseases, psychological disorders, strokes, head injuries or development deficiencies.

Its core product uses neural networks and clinical data to assess a patient’s condition and provide personalized digital therapies such as cognitive training tasks.

Bloks (00325.HK)

Shares in Chinese toymaker Bloks has surged 94% since its debut, thanks to overwhelming demand in the city.

The $3.8 billion firm, which specialises in assembling Transformers and other figurines, is tapping into the country's collectible toy frenzy led by Hong Kong-listed peer Pop Mart, whose stock clocked up a blistering 360% gain in 2024.

Founded in 2014 with focus on lego-like building blocks, the company jumped into figurines in 2022, with the majority of its revenue coming from the latter business now. Despite of rapid growth in revenue in recent years, Bloks has been unprofitable since at least 2021, according to its prospectus.

Bloks’s IPO demand was also helped by an abundance of zero-interest loans made available for the purchase of the stock. Individuals sought around HK$879 billion ($113 billion) in margin financing to participate in the IPO, reflecting around 6,000 times the number of shares initially set aside for them. The excess demand was greater than blockbuster IPO from Mao Geping Cosmetics Co.

InnoScience (02577.HK)

Shares of InnoScience made their Hong Kong trading debut at the end of last year, becoming a relatively rare new semiconductor listing in Hong Kong from a company wooing investors with its proprietary technology used in a new generation of gallium nitride (GaN) microchips. The shares has jumped about 69% since its IPO.

Founded in 2017, InnoScience is a leading global player in the latest generation of microchips made with a combination of GaN and traditional silicon technology. GaN-silicon competes with another technology called silicon carbide (SiC) for use in the most cutting-edge chips, with SiC considered the more mature of the pair.

InnoScience has been included as an eligible stock in both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective March 10, 2025. This inclusion is expected to broaden the company’s investor base, increase trading liquidity, and enhance its interaction with investors in mainland China, reflecting increased recognition of its operating performance and growth potential.

Minieye (02431.HK)

Minieye Technology debuted on the Hong Kong Stock Exchange (HKEX) on December 27, 2024, becoming the latest Chinese intelligent driving firm to go public. The shares has jumped about 57% since its IPO.

Founded in 2014, Minieye supplies intelligent driving systems, smart cockpits, and vehicle-road collaboration solutions. Its product lines include “iSafety,” which supports advanced driver-assistance systems, and “iPilot,” which targets higher-level autonomous capabilities like highway navigation and intelligent parking.

Over the years, Minieye has established itself as a key player in intelligent driving. According to Sina, as of mid-2024, its technologies were used by 35 automakers, including 21 export models destined for Europe, Australia, the UK, and Southeast Asia. Minieye is among the first Chinese companies to secure EU General Safety Regulation (GSR) certifications and has contributed to achieving five-star European New Car Assessment Programme (Euro NCAP) safety ratings.